Epigenetics of cancer progression

Pharmacogenomics

Volumn 9, Issue 2, 2008, Pages 215-234

  Vucic, Emily A ^a,b   Brown, Carolyn J ^b   Lam, Wan L ^a,b  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cancer progression; CpG islands; DNA methylation; Epigenetic methods and technologies; Epigenetic therapeutics; Epigenetics; Histone deacetylase inhibitors; Histone modifications; Methyl inhibiting nucleoside analogues; SiRNA

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; BUTYRIC ACID; CATECHIN; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; NUCLEOSIDE ANALOG; PROCAINAMIDE; PROCAINE; RG 108; ROMIDEPSIN; SMALL INTERFERING RNA; TRAPOZIN A; TRAPOZIN B; TRICHOSTATIN A; TRICHOSTATIN B; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE; HISTONE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; CARDIOTOXICITY; CHROMOSOMAL INSTABILITY; CHROMOSOME REARRANGEMENT; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CPG ISLAND; CUTANEOUS T CELL LYMPHOMA; DEMETHYLATION; DNA METHYLATION; DNA SEQUENCE; ENVIRONMENTAL FACTOR; EPIGENETICS; EPILEPSY; GENE EXPRESSION REGULATION; GENOME IMPRINTING; HEART ARRHYTHMIA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MARKER GENE; MONOZYGOTIC TWINS; MYELODYSPLASTIC SYNDROME; NEOPLASM; NONHUMAN; NUTRITIONAL HEALTH; OPTIMAL DRUG DOSE; POSTTRANSCRIPTIONAL GENE SILENCING; PROSTATE CANCER; REVIEW; UNSPECIFIED SIDE EFFECT; X CHROMOSOME INACTIVATION; ANIMAL; DISEASE COURSE; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; DISEASE PROGRESSION; DNA METHYLATION; HISTONES; HUMANS; NEOPLASMS; RNA, SMALL INTERFERING;

EID: 42449102138     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.2.215     Document Type: Review

References (230)

1. Feinberg AP, Ohlsson R, Henikoff S: The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 7, 21-33 (2006).
2. Esteller M, Herman JG: Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J. Pathol. 196, 1-7 (2002).
3. Feinberg AP, Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301, 89-92 (1983).
4. Esteller M, Levine R, Baylin SB et al.: MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 17, 2413-2417 (1998).
5. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3, 415-428 (2002).
6. Costello JF, Fruhwald MC, Smiraglia DJ et al.: Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. 24, 132-138 (2000).
7. Glasspool RM, Teodoridis JM, Brown R: Epigenetics as a mechanism driving polygenic clinical drug resistance. Br. J. Cancer 94, 1087-1092 (2006).
8. Chekhun VF, Lukyanova NY, Kovalchuk O et al.: Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets. Mol. Cancer Ther. 6, 1089-1098 (2007).
9. Abbosh PH, Montgomery JS, Starkey JA et al.: Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Cancer Res. 66, 5582-5591 (2006).
10. Baker EK, Johnstone RW, Zalcberg JR et al.: Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 24, 8061-8075 (2005).
11. Wei SH, Chen CM, Strathdee G et al.: Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin. Cancer Res. 8, 2246-2252 (2002).
12. Wei SH, Balch C, Paik HH et al.: Prognostic DNA methylation biomarkers in ovarian cancer. Clin. Cancer Res. 12, 2788-2794 (2006).
13. Yanagawa N, Tamura G, Cizumi H et al.: Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer 58, 131-138 (2007).
14. Hollick JB, Patterson GI, Coe EH Jr et al.: Allelic interactions heritably alter the activity of a metastable maize pl allele. Genetics 141, 709-719 (1995).
15. Paro R, Strutt H, Cavalli G: Heritable chromatin states induced by the Polycomb and trithorax group genes. Novartis Found. Symp. 214, 51-61; discussion 61-56, 104-113 (1998).
16. Morgan HD, Sutherland HG, Martin DI et al.: Epigenetic inheritance at the agouti locus in the mouse. Nat. Genet. 23, 314-318 (1999).
17. Drake AJ, Walker BR, Seckl JR: Intergenerational consequences of fetal programming by in utero exposure to glucocorticoids in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288, R34-R38 (2005).
18. Hitchins MP, Wong JJ, Suthers G et al.: Inheritance of a cancer-associated MLH1 germ-line epimutation. N. Engl. J. Med. 356, 697-705 (2007).
19. Suter CM, Martin DI, Ward RL: Gemline epimutation of MLH1 in individuals with multiple cancers. Nat. Genet. 36, 497-501 (2004).
20. Tahiliani M, Mei P, Fang R et al.: The histone H3K4 demethylase SMCX links REST target genes to X-linked mental retardation. Nature 447, 601-605 (2007).
21. Boyer LA, Plath K, Zeitlinger J et al.: Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 441, 349-353 (2006).
22. Lee TI, Jenner RG, Boyer LA et al.: Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125, 301-313 (2006).
23. Bernstein BE, Mikkelsen TS, Xie X et al.: A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125, 315-326 (2006).
24. Weber M, Hellmann I, Stadler MB et al.: Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat. Genet. 39, 457-466 (2007).
25. Gama-Sosa MA, Midgett RM, Slagel VA et al.: Tissue-specific differences in DNA methylation in various mammals. Biochim. Biophys. Acta. 740, 212-219 (1983).
26. Bird A: DNA methylation patterns and epigenetic memory. Genes Dev. 16, 6-21 (2002).
27. Ehrlich M, Gama-Sosa MA, Huang LH et al.: Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. Nucleic Acids Res. 10, 2709-2721 (1982).
28. Jaenisch R, Bird A: Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. 33(Suppl.), 245-254 (2003).
29. Haaf T: Methylation dynamics in the early mammalian embryo: implications of genome reprogramming defects for development. Curr. Top. Microbiol. Immunol. 310, 13-22 (2006).
30. Jones PA, Wolkowicz MJ, Rideout WM 3rd et al.: De novo methylation of the MyoD1 CpG island during the establishment of immortal cell lines. Proc. Natl Acad. Sci. USA 87, 6117-6121 (1990).
31. Shilatifard A: Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu. Rev. Biochem. (2006).
32. Schubeler D, MacAlpine DM, Scalzo, D et al.: The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev. 18, 1263-1271 (2004).
33. Strahl BD, Alls CD: The language of covalent histone modifications. Nature 403, 41-45 (2000).
34. Ausio J, Levin DB, de Amorim GV et al.: Syndromes of disordered chromatin remodeling. Clin. Genet. 64, 83-95 (2003).
35. Santos-Rosa H, Caldas C: Chromatin modifier enzymes, the histone code and cancer. Eur. J. Cancer 41, 2381-2402 (2005).
36. Guenther MG, Levine SS, Boyer LA et al.: A chromatin landmark and transcription initiation at most promoters in human cells. Cell 130, 77-88 (2007).
37. Agger K, Cloos PA, Christensen J et al.: UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 449, 731-734 (2007).
38. Mikkelsen TS, Ku M, Jaffe DB et al.: Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 448, 553-560 (2007).
39. Iimura T, Pourquie O: HOX genes in time and space during vertebrate body formation. Dev. Growth Differ. 49, 265-275 (2007).
40. Jones PL, Veenstra GJ, Wade PA et al.: Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 19, 187-191 (1998).
41. Gray SG, Iglesias AH, Lizcano F et al.: Functional characterization of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein. J. Biol. Chem. 280, 28507-28518 (2005).
42. Cloos PA, Christensen J, Agger K et al.: The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on bistone H3. Nature 442, 307-311 (2006).
43. Yang ZQ, Imoto I, Fukuda Y et al.: Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines. Cancer Res. 60, 4735-4739 (2000).
44. Kouzarides T: Chromatin modifications and their function. Cell 128, 693-705 (2007).
45. Mayer W, Nivelea u A, Walter J et al.: Demethylation of the zygotic paternal genome. Nature 403, 501-502 (2000).
46. Nan X, Ng HH, Johnson CA et al.: Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393, 386-389 (1998).
47. Fuks F, Burgers WA, Godin N et al.: Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J. 20, 2536-2544 (2001).
48. Lehnertz B, Ueda Y, Derijck AA et al.: Suv39h-mediated histone H3 iysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin. Curr Biol. 13, 1192-1200 (2003).
49. Varambally S, Dhanasekaran SM, Zhou M et al.: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629 (2002).
50. Kleer CG, Cao Q, Varambally S et al.: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100, 11606-11611 (2003).
51. Cha TL, Zhou BP, Xia W et al.: Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 310, 306-310 (2005).
52. Vire E, Brenner C, Deplus R et al.: The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439, 871-874 (2006).
53. Hamilton AJ, Baulcombe DC: A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 286, 950-952 (1999).
54. Tijsterman M, Ketting RF, Plasterk RH: The genetics of RNA silencing. Annu. Rev. Genet. 36, 489-519 (2002).
55. Guo S, Kemphues KJ: Par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. Cell 81, 611-620 (1995).
56. Wassenegger M, Heimes S, Riedel L et al.: RNA-directed de novo methylation of genomic sequences in plants. Cell 76, 567-576 (1994).
57. Svoboda P, Stein P, Hayashi H et al.: Selective reduction of dormant maternal mRNAs in mouse oocytes by RNA interference. Development 127, 4147-4156 (2000).
58. Fire A, Xu S, Montgomery MK et al.: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811 (1998).
59. Hannon GJ: RNA interference. Nature 418, 244-251 (2002).
60. Ting AH, Schuebel KE, Herman JG et al.: Short double-stranded RNA induces transcriptional gene silencing in human cancer cells in the absence of DNA methylation. Nat. Genet. 37, 906-910 (2005).
61. Castanotto D, Tommasi S, Li M et al.: Short hairpin RNA-directed cytosine (CpG) methylation of the RASSF1A gene promoter in HeLa cells. Mol. Ther. 12, 179-183 (2005).
62. Hartig JV, Tomari Y, Forstemann K: piRNAs-the ancient hunters of genome invaders. Genes Dev. 21, 1707-1713 (2007).
63. Volpe TA, Kidner C, Hall IM et al.: Regulation of heterochromatic silencing and histone H3 lysine-9 methylation by RNAi. Science 297, 1833-1837 (2002).
64. Pal-Bhadra M, Bhadra U, Birchler JA: RNAi related mechanisms affect both transcriptional and posttranscriptional transgene silencing in Drosophila. Mol. Cell 9, 315-327 (2002).
65. Verdel A, Jia S, Gerber S et al.: RNAi-mediated targeting of heterochromatin by the RITS complex. Science 303, 672-676 (2004).
66. Kanellopoulou C, Muljo SA, Kung AL et al.: Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes Dev. 19, 489-501 (2005).
67. Murchison EP, Partridge JF, Tam OH et al.: Characterization of Dicer-deficient murine embryonic stem cells. Proc. Natl Acad. Sci. USA 102, 12135-12140 (2005).
68. Wilson VL, Smith RA, Ma S et al.: Genomic 5-methyldeoxycytidine decreases with age. J. Biol. Chem. 262, 9948-9951 (1987).
69. Li E, Beard C, Jaenisch R: Role for DNA methylation in genomic imprinting. Nature 388, 362-365 (1993).
70. Zhou Z, Hong EJ, Cohen S et al.: Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth and spine maturation. Neuron 52, 255-269 (2006).
71. Hendrich B, Guy J, Ramsahoye B et al.: Closely related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse development. Genes Dev. 15, 710-723 (2001).
72. Xu GL, Bestor TR, Bourc'his D et al.: Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 402, 187-191 (1999).
73. Jeanpierre M, Turleau C, Aurias A etal.: An embryonic-like methylation pattern of classical satellite DNA is observed in ICF syndrome. Hum. Mol. Genet. 2, 731-735 (1993).
74. Lewis A, Murrell A: Genomic imprinting: CTCF protects the boundaries. Curr. Biol. 14, R284-R286 (2004).
75. Steenman MJ, Rainier S, Dobry CJ et al.: Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nat. Genet. 7, 433-439 (1994).
76. Feinberg. AP: Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: an introduction. Cancer Res. 59, S1743-S1746 (1999).
77. Cui H, Onyango P, Brandenburg S et al.: Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res. 62, 6442-6446 (2002).
78. Murphy SK, Huang Z, Wen Y et al.: Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. Mol. Cancer Res. 4, 283-292 (2006).
79. Falls JG, Pullord DJ, Wylie AA et al.: Genomic imprinting: implications for human disease. Am. J. Pathol. 154, 635-647 (1999).
80. Ohlsson R: Loss of IGF2 imprinting: mechanisms and consequences. Novartis Found. Symp. 262, 108-121: discussion 121-104, 265-108 (2004).
81. Robinson WP, Lalande M: Sex-specific meiotic recombination in the Prader-Willi/Angelman syndrome imprinted region. Hum. Mol. Genet. 4, 801-806 (1995).
82. Paidi A, Gyapay G, Jami J: Imprinted chromosomal regions of the human genome display sex-specific meicotic recombination frequencies, Curr Biol. 5, 1036-1035 (1995).
83. Sandovici I, Kassovska-Bratinova S, Vaughan JE et al.: Human imprinted chromosomal regions are historical hot-spots of recombination. PLoS Genet. 2, E101 (2006).
84. Brown CJ, Greally JM: A stain upon the silence: genes escaping X inactivation. Trends Genet. 19, 432-438 (2003).
85. Brown CJ, Ballabio, A, Rupert JL et al.: A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome. Nature 349, 38-44 (1991).
86. Brown CJ, Lafreniere RG, Powers VE et al.: Localization of the X inactivation centre on the human X chromosome in Xq13. Nature 349, 82-84 (1991).
87. Chang SC, Tucker T, Thorogood NP et al.: Mechanisms of X-chromosome inactivation. Front. Biosci. 11, 852-866 (2006).
88. Brown CJ: Skewed X-chromosome inactivation: cause or consequence? J. Natl Cancer Inst. 91, 304-305 (1999).
89. Li G, Su Q, Liu GQ et al.: Skewed X chromosome inactivation of blood cells is associated with early development of lung cancer in females. Oncol. Rep. 16, 859-864 (2006).
90. Helbling-Leclere A, Lenoir GM, Feunteun J: Heterozygote BRCA1 status and skewed chromosome X inactivation. Fam. Cancer. 6, 153-157 (2007).
91. Brix TH, Knudsen GP, Kristiansen M et al.: High frequency of skewed X-chromosome inactivation in females with autoimmune thyroid disease: a possible explanation for the female predisposition to thyroid autoimmunity. J. Clin. Endocrinol. Metab. 90, 5949-5953 (2005).
92. Xu J, Meyers D, Freije D et al.: Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat. Genet. 20, 175-179 (1998).
93. Kristiansen M, Knudsen GP, Maguire P et al.: High incidence of skewed X chromosome inactivation in young patients with familial non-BRCA1/BRCA2 breast cancer. J. Med. Genet. 42, 877-880 (2005).
94. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100, 57-70 (2000).
95. Baylin SB, Belinsky SA, Herman JG: Aberrant methylation of gene promoters in cancer - concepts, misconcepts, and promise. J. Natl Cancer Inst. 92, 1460-1461 (2000).
96. Catteau A, Harris WH, Xu CF et al.: Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 18, 1957-1965 (1999).
97. Cui H, Cruz-Correa M, Giardiello FM et al.: Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 299, 1753-1755 (2003).
98. Dobrovic A, Simpfendorfer D: Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res. 57, 3347-3350 (1997).
99. Egger G, Liang G, Aparicio A et al.: Epigenetics in human disease and prospects for epigenetic therapy. Nature 429, 457-463 (2004).
100. Widschwendter M, Jones PA: DNA methylation and breast carcinogenesis. Oncogene 21, 5462-5482 (2002).
101. Bowman RV, Yang IA, Semmler AB et al.: Epigenetics of lung cancer. Respirology 11, 355-365 (2006).
102. Nelson WG, Yegnasubramanian S, Agoston AT et al.: Abnormal DNA methylation, epigenetics, and prostate cancer. Front. Biosci. 12, 4254-4266 (2007).
103. Ahmed FE: Colorectal cancer epigenetics: the role of environmental factors and the search for molecular biomarkers. J. Environ. Sci. Health C. Environ. Carcinog. Ecotoxicol. Rev. 25, 101-154 (2007).
104. Worthley DL, Whitehall VL, Spring KJ et al.: Colorectal carcinogenesis: road maps to cancer. World J Gastroenterol. 13, 3784-3791 (2007).
105. Macaluso M, Paggi MG, Giordano A: Genetic and epigenetic alterations as hallmarks of the intricate road to cancer. Oncogene 22, 6472-6478 (2003).
106. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61, 759-767 (1990).
107. Fearon ER, Hamilton SR, Vogelstein B: Clonal analysis of human colorectal-tumors. Science 238, 193-197 (1987).
108. He TC, Sparks AB, Rago C et al.: Identification of c-MYC as a target of the APC pathway. Science 281, 1509-1512 (1998).
109. Jaiswal AS, Marlow BP, Gupta N et al.: β-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 21, 8414-8427 (2002).
110. Mann B, Gelos M, Siedow A et al. Target genes of β-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc. Nad Acad. Sci. USA 96, 1603-1608 (1999).
111. Brenner C, Deplus R, Didelot C et al.: Myc represses transcription through recruitment of DNA methyltransferase corepressor. EMBO J. 24, 336-346 (2005).
112. Levens DL: Reconstructing MYC. Genes Dev. 17, 1071-1077 (2003).
113. Gumbiner BM: Regulation of cadherin-mediated adhesion in morphogenesis. Nat. Rev. Mol. Cell. Biol. 6, 622-634 (2005).
114. Rao SP, Rechsteiner MP, Berger C et al.: Zebularine reactivates silenced E-cadherin but unlike 5-Azacytidine does not induce switching from latent to lytic Epstein-Barr virus infection in Burkitt's lymphoma Akata cells. Mol. Cancer 6, 3 (2007).
115. Hiltunen MO, Kolstinaho, J, Alhonen L et al.: Hypermethylation of the WT1 and calcitonin gene promoter regions at chromosome 11 p in human colorectal cancer. Br. J. Cancer 76, 1124-1130 (1997).
116. Suzuki H, Watkins DN, Jair KW et al.: Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet. 36, 417-422 (2004).
117. Bellacosa, A: Genetic hits and mutation rate in colorectal tumorigenesis: versatility of Knudson's theory and implications for cancer prevention. Genes Chromosomes Cancer 38, 382-388 (2003).
118. Gatalica Z, Torlakovic E: Pathology of the hereditary colorectal carcinoma. Fam. Cancer (2007) (Epub ahead of print).
119. Wallner M, Herbst A, Behrens A et al.: Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin. Cancer Res. 12, 7347-7352 (2006).
120. Herman JG, Umar A, Polyak K et al.: Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl Acad. Sci. USA 95, 6870-6875 (1998).
121. Krtolica K, Krajnovic M, Usaj-Knezevic S et al.: Comethylation of p16 and MGMT genes in colorectal carcinoma: correlation with clinicopathological features and prognostic value. World J. Gastroenterol. 13, 1187-1194 (2007).
122. Deng G, Chen A, Hong J et al.: Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res. 59, 2029-2033 (1999).
123. Renkonen E, Zhang Y, Lohi H et al.: Altered expression of MLH1, MSH2, and MSH6 in predisposition to hereditary nonpolyposis colorectal cancer. J. Clin. Oncol. 21, 3629-3637 (2003).
124. Young J, Simms LA, Biden KG et al.: Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am. J. Pathol. 159, 2107-2116 (2001).
125. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 60, 2368-2371 (2000).
126. Gazzoli I, Loda M, Garber J et al.: A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res. 62, 3925-3928 (2002).
127. Toyota M, Ahuja N, Ohe-Toyota M et al.: CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA 96, 8681-8686 (1999).
128. Weisenberger DJ, Siegmund KD, Campan M et al.: CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 38, 787-793 (2006).
129. Bird AP: CpG-rich islands and the function of DNA methylation. Nature 321, 209-213 (1986).
130. Shames DS, Girard L, Gao B et al.: A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med. 3, E486 (2006).
131. Park HW, Kang HC, Kim IJ et al.: Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers. Int. J. Cancer 120, 7-12 (2007).
132. Esteller M, Sanchez-Cespedes M, Rosell R et al.: Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59, 67-70 (1999).
133. Palmisano WA, Divine KK, Saccomanno G et al: Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60, 5954-5958 (2000).
134. Esteller M, Silva JM, Dominguez G et al.: Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 92, 564-569 (2000).
135. Corn PG, Kuerbitz SJ, van Noesel MM et al.: Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′CpG island methylation. Cancer Res. 59, 3352-3356 (1999).
136. Esteller M, Guo M, Moreno V et al.: Hypermethylation-associated inactivation of the cellular retinol-binding-protein 1 gene in human cancer. Cancer Res. 62, 5902-5905 (2002).
137. Claus R, Lubbert M: Epigenetic targets in hematopoietic malignancies. Oncogene 22, 6489-6496 (2003).
138. Yates DR, Rehman I, Abbod MF et al.: Promoter hypermethylation identifies progression risk in bladder cancer. Clin. Cancer Res. 13, 2046-2053 (2007).
139. Holst CR, Nuovo GJ, Esteller M et al.: Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res. 63, 1596-1601 (2003).
140. Tisty TD, Crawford YG, Holst CR et al.: Genetic and epigenetic changes in mammary epithelial cells may mimic early events in carcinogenesis. J. Mammary Gland Biol. Neoplasia 9, 263-274 (2004).
141. Ushijima T: Detection and interpretation of altered methylation patterns in cancer cells. Nat. Rev. Cancer. 5, 223-231 (2005).
142. Paluszczak J, Baer-Dubowska W: Epigenetic diagnostics of cancer - the application of DNA methylation markers. J. Appl. Genet. 47, 365-375 (2006).
143. Laird PW: The power and the promise of DNA methylation markers. Nat. Rev. Cancer 3, 253-266 (2003).
144. Miyamoto K, Ushijima T: Diagnostic and therapeutic applications of epigenetics. Jpn. J. Clin. Oncol. 35, 293-301 (2005).
145. Herman JG, Graff JR, Myohanen S et al.: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 93, 9821-9826 (1996).
146. Belinsky SA, Liechty KC, Gentry FD et al.: Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res. 66, 3338-3344 (2006).
147. Cui H, Horon IL, Ohlsson R et al.: Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat. Med. 4, 1276-1280 (1998).
148. Roupret M, Hupertan V, Catto JW et al.: Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. Int. J. Cancer 122, 952-956 (2007).
149. Bastian PJ, Ellinger J, Wellmann A et al.: Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin. Cancer Res. 11, 4097-4106 (2005).
150. Gonzalgo ML, Pavlovich CP, Lee SM et al.: Prostate cancer detection by GSTP1 methylation analysis of posthiopsy urine specimens. Clin. Cancer Res. 9, 2673-2677 (2003).
151. Cairns P, Esteller M, Herman JG et al.: Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin. Cancer Res. 7, 2727-2730 (2001).
152. Goessl C, Krause H, Muller M et al.: Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res. 60, 5941-5945 (2000).
153. Dulaimi E, Uzzo RG, Greenberg RE et al.: Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin. Cancer Res. 10, 1887-1893 (2004).
154. Taback B, Giuliano AE, Lai R et al.: Epigenetic analysis of body fluids and tumor tissues: application of a comprehensive molecular assessment for early-stage breast cancer patients. Ann. NY Acad. Sci. 1075, 211-221 (2006).
155. Hoque MO, Feng Q, Toure P et al.: Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J. Clin. Oncol. 24, 4262-4269 (2006).
156. Quintieri L, Fantin M, Vizler C: Identification of molecular determinants of tumor sensitivity and resistance to anticancer drugs. Adv. Exp. Med. Biol. 593, 95-104 (2007).
157. Fearon ER: BRCA1 and E-cadherin promoter hypermethylation and gene inactivation in cancer-association or mechanism? J. Natl Cancer. Inst. 92, 515-517 (2000).
158. Bird AP: DNA methylation - how important in gene control? Nature 307, 503-504 (1984).
159. Frigola J, Song J, Stirzaker C et al.: Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat. Genet. 38, 540-549 (2006).
160. Julien S, Puig I, Caretti E et al.: Activation of NF-κB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene 26, 7445-7456 (2007).
161. Cano A, Perez-Moreno MA, Rodrigo I et al.: The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2, 76-83 (2000).
162. Jacobs JJ, Kieboom K, Marino S et al.: The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397, 164-168 (1999).
163. Lorincz MC, Schubeler D: RNA polymerase II: just stopping by. Cell 130, 16-18 (2007).
164. Zinn RL, Pruitt K, Eguchi S et al.: hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Res. 67, 194-201 (2007).
165. Eden A, Gaudet F, Waghmare A et al.: Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300, 455 (2003).
166. Ehrlich M: Cancer-linked DNA hypomethylation and its relationship to hypermethylation. Curr. Top. Microbiol. Immunol. 310, 251-274 (2006).
167. Ehrlich M: DNA methylation in cancer: too much, but also too little. Oncogene 21, 5400-5413 (2002).
168. Wilson AS, Power BE, Molloy PL: DNA hypomethylation and human diseases. Biochim. Biophys. Acta. 1775, 138-162 (2007).
169. Ehrlich M: DNA hypomethylation, cancer, the immunodeficiency, centromeric region instability, facial anomalies syndrome and chromosomal rearrangements. J. Nutr. 132, 2424S-2429S (2002).
170. Panning B, Jaenisch R: DNA hypomethylation can activate Xist expression and silence X-linked genes. Genes Dev. 10, 1991-2002 (1996).
171. Hoffmann MJ, Schulz WA: Causes and consequences of DNA hypomethylation in human cancer. Biochem. Cell Biol. 83, 296-321 (2005).
172. Suter CM, Martin DI, Ward RL: Hypomethylation of L1 retrotransposons in colorectal cancer and adjacent normal tissue. Int. J. Colorectal Dis. 19, 95-101 (2004).
173. Itano O, Ueda M, Kikuchi K et al.: Correlation of postoperative recurrence in hepatocellular carcinoma with demethylation of repetitive sequences. Oncogene 21, 789-797 (2002).
174. Qu G, Dubeau L, Narayan A et al.: Satellite DNA hypomethylation vs overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential. Mutat. Res. 423, 91-101 (1999).
175. Widschwendter M, Jiang G, Woods C et al.: DNA hypomethylation and ovarian cancer biology. Cancer Res. 64, 4472-4480 (2004).
176. Narayan A, Ji W, Zhang XY et al.: Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int. J. Cancer. 77, 833-838 (1998).
177. Weisenberger DJ, Campan M, Long TI et al.: Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res. 33, 6823-6836 (2005).
178. Roman-Gomez J, Jimenez-Velasco A, Agirre X et al.: Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome. Leukemia 20, 1445-1448 (2006).
179. Florl AR, Lower R, Schmitz-Drager BJ et al.: DNA methylation and expression of LINE-1 and HERV-K provirus sequences in urothelial and renal cell carcinomas. Br. J. Cancer 80, 1312-1321 (1999).
180. Hernandez R, Frady A, Zhang XY et al.: Preferential induction of chromosome 1 multibranched figures and whole-arm deletions in a human pro-B cell line treated with 5-azacytidine or 5-azadeoxycytidine. Cytogenet. Cell Genet. 76, 196-201 (1997).
181. Xin H, Yoon HG, Singh PB et al.: Components of a pathway maintaining histone modification and heterochromatin protein 1 binding at the pericentric heterochromatin in mammalian cells. J. Biol. Chem. 279, 9539-9546 (2004).
182. Stancheva I, El-Maarri O, Walter J et al.: DNA methylation at promoter regions regulates the timing of gene activation in Xenopus laevis embryos. Dev. Biol. 243, 155-165 (2002).
183. Nishigaki M, Aoyagi K, Danjoh I et al.: Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays. Cancer Res. 65, 2115-2124 (2005).
184. de Smet C, De Backer O, Faraoni I et al.: The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc. Natl Acad Sci. USA 93, 7149-7153 (1996).
185. Nakamura N, Takenaga K: Hypomethylation of the metastasis-associated S100A4 gene correlates with gene activation in human colon adenocarcinoma cell lines. Clin. Exp. Metastasis 16, 471-479 (1998).
186. Okada H, Kimura MT, Tan D et al.: Frequent trefoil factor 3 ( TFF3) overexpression and promoter hypomethylation in mouse and human hepatocellular carcinomas. Int. J. Oncol. 26, 369-377 (2005).
187. Sato N, Maitra A, Fukushima N et al.: Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res. 63, 4158-4166 (2003).
188. Frigola J, Sole X, Paz MF et al.: Differential DNA hypermethylation and hypomethylation signatures in colorectal cancer. Hum. Mol. Genet. 14, 319-326 (2005).
189. Paz MF, Fraga MF, Avila S et al.: A systematic profile of DNA methylation in human cancer cell lines. Cancer Res. 63, 1114-1121 (2003).
190. Fraga MF, Ballestar E, Paz MF et al.: Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl Acad Sci. USA 102 10604-10609 (2005).
191. Poulsen P, Esteller M, Vaag A et al.: The epigenetic basis of twin discordance in age-related diseases. Pediatr Res. 61, 38R-42R (2007).
192. Poulsen F, Vaag AA, Kyvik KO et al.: Low birth weight is associated with NIDDM in discordant monozygotic and dizygotic twin pairs. Diabetologia, 40, 439-446 (1997).
193. Lachmann RH, Grant IR, Halsall D et al.: Twin pairs showing discordance of phenotype in adult Gaucher's disease. Q. J. Med. 97, 199-204 (2004).
194. Wong AH, Gottesman II, Petronis A: Phenotypic differences in genetically identical organisms: the epigenetic perspective. Hum. Mol. Genet. 14(1), R11-R18 (2005).
195. Petronis A: Epigenetics and twins: three variations on the theme. Trends Genet. 22, 347-350 (2006).
196. Feil R: Environmental and nutritional effects on the epigenetic regulation of genes. Mutat. Res. 600, 46-57 (2006).
197. Wolff GL, Kodell RL, Moore SR et al.: Maternal epigenetics and methyl supplements affect agouti gene expression in Avy/a mice. FASEB J. 12, 949-957 (1998).
198. Waterland RA, Jirtle RL: Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol. Cell Biol. 23, 5293-5300 (2003).
199. Dolinoy DC, Weidman JR, Jirtle RL: Epigenetic gene regulation: linking early developmental environment to adult disease. Reprod. Toxicol. 23, 297-307 (2007).
200. Waterland RA, Lin JR, Smith CA et al.: Post-weaning diet affects genomic imprinting at the insulin-like growth factor 2 (Igf2) locus.
201. Hu M, Yao J, Cai L et al.: Distinct epigenetic changes in the stromal cells of breast cancers. Nat. Genet. 37, 899-905 (2005).
202. Hodge DR, Peng B, Cherry JC et al.: Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res. 65, 4673-4682 (2005).
203. Meng F, Wehbe-Janek H, Henson R et al.: Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene (2007) (Epub ahead of print).
204. Brueckner B, Kuck D, Lyko F: DNA methyltransferase inhibitors for cancer therapy. Cancer J. 13, 17-22 (2007).
205. Gore SD: Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies. Nat. Clin. Pract. Oncol. 2(Suppl. 1), S30-S35 (2005).
206. Candelaria, M, Gallardo-Rincon D, Arce C et al.: A Phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann. Oncol. 18, 1529-1538 (2007).
207. Sato M, Vaughan MB, Girard L et al.: Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res. 66, 2116-2128 (2006).
208. Hatada I, Hayashizaki Y, Hirotsune S et al.: A genomic scanning method for higher organisms using restriction sites as landmarks. Proc. Natl Arad Sci. USA 88, 9523-9527 (1991).
209. Frommer M, McDonald LE, Millar DS et al.: A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl Acad. Sci. USA 89, 1827-1831 (1992)
210. Gonzalgo ML, Liang G, Spruck CH 3rd et al.: Identification and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR. Cancer Res. 57, 594-599 (1997).
211. Huang TH, Laux DE, Hamlin BC et al.: Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique. Cancer Res. 57, 1030-1034 (1997).
212. Singer-Sam J, Grant M, LeBon JM et al.: Use of a HpaII-polymerase chain reaction assay to study DNA methylation in the Pgk-1 CpG island of mouse embryos at the time of X-chromosome inactivation. Mol. Cell Biol. 10 4987-4989 (1990).
213. Yan PS, Chen CM, Shi H et al.: Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. Cancer Res. 61, 8375-8380 (2001).
214. Xiong Z, Laird PW: COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 25, 2532-2534 (1997).
215. Frigola J, Ribas M, Risques RA et al.: Methylome profiling of cancer cells by amplification of inter-methylated sites (AIMS). Nucleic Acids Res. 30, E28 2002).
216. Gitan RS, Shi H, Chen CM et al.: Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis. Genome Res. 12, 158-164 (2002).
217. Estecio MR, Yan PS, Ibrahim AE et al.: High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res. 17, 1529-1536 (2007).
218. Weber M, Davies JJ, Wittig D et al.: Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat. Genet. 37, 853-862 (2005).
219. Wilson IM, Davies JJ, Weber M et al.: Epigenomics: mapping the methylome. Cell Cycle 5, 155-158 (2006).
220. Ballestar E, Paz MF, Valle L et al.: Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J. 22, 035-6345 (2003).
221. Wu J, Smith LT, Plass C et al.: ChIP-chip comes of age for genome-wide functional analysis. Cancer Res. 66, 6899-6902 (2006).
222. Khulan B, Thompson RF, Ye K et al.: Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res. 16, 1046-1055 (2006).
223. Blum W, Klisovic RB, Hackanson B et al.: Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J. Clin. Oncol. 25, 3884-3891 (2007).
224. Sigaiotti L, Fratta E, Coral S et al.: Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J. Cell Pllysiol. 212, 330-344 (2007).
225. Jones PA, Taylor SM: Cellular differentiation, cytidine analogs and DNA methylation. Cell 20, 85-93 (1980).
226. Esteller M: DNA methylation and cancer therapy, new developments and expectations. Curr. Opin. Oncol. 17, 55-60 (2005).
227. Fang M, Chen D, Yang CS: Dietary polyphenols may affect DNA methylation. J. Nutr. 137, 223S-228S (2007).
228. Lee WJ, Shim JY, Zhu BT: Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavenoids. Mol. Pharmacol. 68, 1018-1030 (2005).
229. Fouladi M: Histone deacetylase inhibitors in cancer therapy. Cancer Invest. 24, 521-527 (2006).
230. Duvic M, Vu J: Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin. Investig. Drugs 16, 1111-1120 (2007).